Legal & General Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,523
| Closed | -$6.52K | – | 3606 |
|
|
2023
Q1 | $6.52K | Hold |
3,523
| – | – | ﹤0.01% | 3267 |
|
|
2022
Q4 | $3.91K | Hold |
3,523
| – | – | ﹤0.01% | 3364 |
|
|
2022
Q3 | $8K | Sell |
3,523
-894
| -20% | -$3.17K | ﹤0.01% | 3371 |
|
|
2022
Q2 | $13K | Buy |
4,417
+1,788
| +68% | +$8.7K | ﹤0.01% | 3342 |
|
|
2022
Q1 | $18K | Hold |
2,629
| – | – | ﹤0.01% | 3271 |
|
|
2021
Q4 | $22K | Hold |
2,629
| – | – | ﹤0.01% | 3256 |
|
|
2021
Q3 | $20K | Hold |
2,629
| – | – | ﹤0.01% | 3285 |
|
|
2021
Q2 | $18K | Buy |
2,629
+1,109
| +73% | +$9.21K | ﹤0.01% | 3337 |
|
|
2021
Q1 | $16K | Hold |
1,520
| – | – | ﹤0.01% | 3229 |
|
|
2020
Q4 | $11K | Hold |
1,520
| – | – | ﹤0.01% | 3324 |
|
|
2020
Q3 | $12K | Sell |
1,520
-606
| -29% | -$3.76K | ﹤0.01% | 3180 |
|
|
2020
Q2 | $15K | Hold |
2,126
| – | – | ﹤0.01% | 3202 |
|
|
2020
Q1 | $10K | Sell |
2,126
-879
| -29% | -$5.06K | ﹤0.01% | 3169 |
|
|
2019
Q4 | $25K | Hold |
3,005
| – | – | ﹤0.01% | 3124 |
|
|
2019
Q3 | $10K | Hold |
3,005
| – | – | ﹤0.01% | 3271 |
|
|
2019
Q2 | $15K | Hold |
3,005
| – | – | ﹤0.01% | 3284 |
|
|
2019
Q1 | $19K | Buy |
3,005
+1,064
| +55% | +$5.14K | ﹤0.01% | 3115 |
|
|
2018
Q4 | $7K | Hold |
1,941
| – | – | ﹤0.01% | 3317 |
|
|
2018
Q3 | $13K | Hold |
1,941
| – | – | ﹤0.01% | 3297 |
|
|
2018
Q2 | $15K | Sell |
1,941
-463
| -19% | -$6.68K | ﹤0.01% | 3257 |
|
|
2018
Q1 | $54K | Sell |
2,404
-950
| -28% | -$21.1K | ﹤0.01% | 2719 |
|
|
2017
Q4 | $43K | Buy |
3,354
+636
| +23% | +$9.35K | ﹤0.01% | 2924 |
|
|
2017
Q3 | $42K | Buy |
2,718
+1,167
| +75% | +$16.5K | ﹤0.01% | 2970 |
|
|
2017
Q2 | $21K | Buy |
1,551
+321
| +26% | +$6.87K | ﹤0.01% | 3179 |
|
|
2017
Q1 | $27K | Buy |
+1,230
| New | +$26.1K | ﹤0.01% | 3007 |
|
Other funds holding JNCE
Legal & General Group's JNCE Position: Q2 2023 in Review
Legal & General Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,523 shares — an estimated $6.52K sold.
Legal & General Group first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $54K in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Legal & General Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Legal & General Group sold 3,523 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $6.52K.
- Legal & General Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Legal & General Group's Jounce Therapeutics, Inc. Common Stock position peaked at $54K in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.